• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by iRhythm Technologies Inc. (Amendment)

    2/14/23 3:22:57 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email
    SC 13G/A 1 13ga2_irhythm.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC  20549

    SCHEDULE 13G
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO Section 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO Section 240.13d-2

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)


      iRhythm Technologies, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    450056106
    (Cusip Number)
     
    December 31, 2022
    (Date of Event which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    S
    Rule 13d-1(b)
    ☐
    Rule 13d-1(c)
    ☐
    Rule 13d-1(d)





    13G

    CUSIP No. 450056106

    1
    NAMES OF REPORTING PERSONS
     
    Sands Capital Management, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
     
    (a) ☐      (b) X
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
     
    SHARES BENEFICIALLY
    OWNED BY
     
    EACH
     
    REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    1,763,046
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    2,667,428
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,667,428
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
     
    ☐
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.1%
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IA




    13G

    CUSIP No. 450056106

    1
    NAMES OF REPORTING PERSONS
     
    Frank M. Sands
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
     
    (a) ☐      (b) X
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
     
    SHARES BENEFICIALLY
    OWNED BY
     
    EACH
     
    REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    1,763,046
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    2,667,428
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,667,428
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
     
    ☐
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.1%
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN, HC




    This Amendment No. 2 to Schedule 13G amends and restates in its entirety the Schedule 13G initially filed on January 12, 2021 (together with all prior and current amendments thereto, this “Schedule 13G”).

    Item 1. Issuer

    (a) Name of Issuer:

    iRhythm Technologies, Inc. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices:

    699 8th Street, Suite 600
    San Francisco, California 94103

    Item 2. Identity and Background

    (a) Name of Person(s) Filing:

    This Schedule 13G is being filed jointly by Sands Capital Management, LLC (“SCM”) and Frank M. Sands (“Sands”).  Sands holds ultimate voting and investment power over securities held by SCM.

    (b) Address of Principal Business Office, or if None, Residence:

    The principal business address of each of SCM and Sands is 1000 Wilson Blvd., Suite 3000, Arlington, VA 22209.

    (c) Citizenship or Place of Organization:

    Sands Capital Management, LLC is organized under the laws of the State of Delaware.  Sands is a citizen of the United States.

    (d) Title of Class of Securities:

    Common Stock, par value $0.001 per share

    (e) CUSIP Number:

    450056106

    Item 3.
    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c),         Check Whether the Person Filing Is an Entity Specified in (a) - (k):


    (a)
    [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);


    (b)
    [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);





    (c)
    [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d)
    [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);


    (e)
    [X] An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f)
    [ ] An employee benefit plan or endowment fund in accordance with
    Section 240.13d-1(b)(1)(ii)(F);


    (g)
    [X] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h)
    [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i)
    [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j)
    [ ] A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k)
    [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___

    SCM is reporting hereunder as an investment adviser pursuant to (e) above.  Sands is reporting hereunder as a control person pursuant to (g) above.

    Item 4. Ownership

    See rows 5 through 11 of cover pages.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be a beneficial owner of more than five percent of the class of securities, check the following [  ].

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

    [X] Securities reported on this Schedule 13G are held in the accounts of various clients of Sands Capital Management, LLC, which may include pension plans, endowments, foundations, mutual funds, charities, state and municipal government entities, Taft-Hartley plans, families, and individuals, among other types.  Such clients have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.  No such client’s interest in the class of securities reported herein is more than 5%.




    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

     See Item 3.

    Item 8.
    Identification and Classification of Members of the Group

    Not applicable.

    Item 9. Notice of Dissolution of Group

    Not applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.



    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.


    Dated: February 14, 2023

     
    /s/ Lisa M. Grozio
     
    Sands Capital Management, LLC
     
    By: Lisa M. Grozio, Chief Compliance Officer
       
     
    /s/ Frank M. Sands
     
    Name: Frank M. Sands




    EXHIBIT INDEX


    EXHIBIT 1
    Joint Acquisition Statement Pursuant to Section 240.13d-1(k)
     




    EXHIBIT 1
    to
    SCHEDULE 13G

    JOINT ACQUISITION STATEMENT
    PURSUANT TO SECTION 240.13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.  The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

    Dated:  February 14, 2023

     
    /s/ Lisa M. Grozio
     
    Sands Capital Management, LLC
     
    By: Lisa M. Grozio, Chief Compliance Officer
       
     
    /s/ Frank M. Sands
     
    Name: Frank M. Sands


    Get the next $IRTC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRTC

    DatePrice TargetRatingAnalyst
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    12/3/2024$86.00Equal Weight
    Wells Fargo
    10/4/2024$78.00Neutral
    Goldman
    6/20/2024$115.00Peer Perform → Outperform
    Wolfe Research
    12/11/2023$110.00Neutral → Buy
    Citigroup
    7/19/2023$130.00Outperform
    Robert W. Baird
    2/7/2023$150.00Overweight
    Wells Fargo
    11/7/2022Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $IRTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm's Zio LTCM Clinical Superiority

    In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, cardiovascular events, and total health care costs.Findings in a younger, commercially insured population build on data from the Medicare fee-for-service, population-based CAMELOT study, confirming the Zio LTCM service's value across patient populations and payer segments. SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced the publication of the real-world evidence study: Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evid

    8/18/25 8:05:00 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm and Lucem Health Partner to Introduce Predictive AI Solution for Early Detection of Arrhythmias in Patient Populations with Comorbid Conditions

    Partnership aims to utilize predictive AI to help identify arrhythmias earlier in patient populations with an elevated risk for arrhythmias to enable timely care for millions who remain undiagnosedCommercial offering from this collaboration designed to support scalable population health and value-based care strategies SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a digital health leader focused on creating trusted solutions that detect, predict, and prevent disease, today announced a strategic partnership with Lucem Health, a leader in AI-driven early disease detection, to accelerate early identification of undiagnosed arrhythmias in patient po

    7/31/25 4:10:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Announces Second Quarter 2025 Financial Results

    SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue of $186.7 million, a 26.1% increase compared to second quarter 2024Gross margin of 71.2%, a 130-basis point increase compared to second quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $545.5 million as of June 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA Recent Operational Highlights

    7/31/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    iRhythm upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded iRhythm from Equal Weight to Overweight and set a new price target of $130.00

    5/2/25 8:03:46 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Wells Fargo resumed coverage on iRhythm with a new price target

    Wells Fargo resumed coverage of iRhythm with a rating of Equal Weight and set a new price target of $86.00

    12/3/24 7:33:58 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Goldman initiated coverage on iRhythm with a new price target

    Goldman initiated coverage of iRhythm with a rating of Neutral and set a new price target of $78.00

    10/4/24 7:40:56 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/5/24 11:59:44 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Patterson Chad bought $20,994 worth of shares (280 units at $74.98) and sold $224,876 worth of shares (3,012 units at $74.66), decreasing direct ownership by 7% to 37,133 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/5/24 5:35:18 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Blackford Quentin S. bought $997,644 worth of shares (9,755 units at $102.27), increasing direct ownership by 8% to 128,510 units (SEC Form 4) (Amendment)

    4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)

    12/6/23 7:08:38 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Rosenbaum Marc Wade sold $35,918 worth of shares (226 units at $158.93), decreasing direct ownership by 2% to 10,879 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/12/25 4:39:08 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Director Talwalkar Abhijit Y exercised 5,312 shares at a strike of $10.71 and sold $839,381 worth of shares (5,312 units at $158.02) (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/12/25 4:38:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Patterson Chad sold $406,168 worth of shares (2,555 units at $158.97), decreasing direct ownership by 6% to 43,667 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/7/25 4:57:37 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    SEC Filings

    View All

    SEC Form 144 filed by iRhythm Technologies Inc.

    144 - iRhythm Technologies, Inc. (0001388658) (Subject)

    8/11/25 4:18:39 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by iRhythm Technologies Inc.

    144 - iRhythm Technologies, Inc. (0001388658) (Subject)

    8/5/25 4:51:34 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by iRhythm Technologies Inc.

    10-Q - iRhythm Technologies, Inc. (0001388658) (Filer)

    7/31/25 5:23:19 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Leadership Updates

    Live Leadership Updates

    View All

    iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

    iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

    2/29/24 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Derrick Sung Joins Aerin Medical as Chief Financial Officer

    A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer

    11/20/23 9:00:00 AM ET
    $IRTC
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

    SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering

    6/6/23 9:00:39 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Financials

    Live finance-specific insights

    View All

    iRhythm Technologies Announces Second Quarter 2025 Financial Results

    SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue of $186.7 million, a 26.1% increase compared to second quarter 2024Gross margin of 71.2%, a 130-basis point increase compared to second quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $545.5 million as of June 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA Recent Operational Highlights

    7/31/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025

    SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, July 31, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading

    7/17/25 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Announces First Quarter 2025 Financial Results

    SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu

    5/1/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 12:54:21 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 9:52:49 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/7/24 4:05:49 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care